Better Therapeutics Announces New CMS HCPCS Code for Prescription Digital Behavioral Therapies (PDTs)
February 28 2022 - 4:01PM
Business Wire
Major step forward towards reimbursement for
software-based treatments including Better Therapeutics’ BT-001 for
the treatment of type 2 diabetes
Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX),
a prescription digital therapeutics (PDT) company developing
cognitive behavioral therapy to address the root causes of
cardiometabolic diseases, announces a new code from the Center for
Medicare and Medicaid Services (CMS) that paves the way for
reimbursement of these therapies. CMS recently created new, Level
II Healthcare Common Procedure Coding Systems (HCPCS) codes for
prescription digital behavioral therapy that will be effective in
April 2022.
“The establishment of these new CMS HCPCS codes provides a clear
pathway towards the adoption and reimbursement of PDTs,” stated
Kevin Appelbaum, Co-Founder and CEO of Better Therapeutics. “PDTs
represent a much-needed advancement and a new standard of care
across a number of therapeutic categories, including type 2
diabetes which is the leading cost driver for Medicare and
Medicaid1. By bringing data-driven, technology-enabled solutions,
PDTs enable an advanced therapeutic approach that is both
patient-focused and highly cost-effective into clinical use. We
applaud CMS for creating the codes as a key step forward for these
important therapeutic programs.”
BT-001 is Better Therapeutics’ PDT delivering cognitive
behavioral therapy to address behavioral root cause of type 2
diabetes. It is currently being studied in a potentially pivotal
study involving 669 patients recruited from six geographic regions
in the U.S. Primary endpoint data will readout in Q1 2022, and the
study is expected to conclude in Q2 2022. The company anticipates
filing a de novo submission with the FDA soon thereafter.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com
1US Health Care Spending by Payer and Health Condition,
1996-2016, JAMA
BTTX-PR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220228006049/en/
Better Therapeutics Media Contact Cassidy McClain
Cassidy.McClain@canalecomm.com +1 619 849 6009
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jul 2023 to Jul 2024